MapLight Therapeutics, Inc. (MPLT)
Healthcare
- Fundamental
- 2
- Sentiment
- 2
- Technical
- 2
Do Nothing: fundamentalScore is 2 and qualitativeScore is 2 — both below the required floor of 3, and the strategy requires fundamentalScore ≥ 3 AND qualitativeScore ≥ 3 before any bullish entry. No tradeable setup exists on the chart either: a pullback/oversold limit would be countertrend (price 10.46 below SMA50 15.17 with MACD line -1.26), and no breakout stop qualifies with price below all key moving averages in a strong downtrend (ADX 34.2); the oversold RSI 29.3 is a bounce-only condition.
Company overview
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for severe central nervous system disorders. Its pipeline includes candidates for schizophrenia, Alzheimer's disease psychosis, autism spectrum disorder, and Parkinson's disease. The company also utilizes a proprietary platform to modulate neural circuits for therapeutic purposes.
Fundamental
weakMapLight Therapeutics has zero revenue and widening losses, offset by a strong cash position and no debt.
MapLight Therapeutics is a pre-revenue clinical-stage CNS biotech with weak fundamentals: zero revenue since inception, losses widening from -$77.6M (2024) to -$161.2M (2025) with H1 2026 already at -$120.9M, and TTM ROE/ROIC near -64%/-69%. The balance sheet is the counterweight — roughly $500M of pro-forma cash after the August 2026 $150M placement, no debt, funding into 2028, and no going-concern qualification. Catalysts are real (positive Phase 2 schizophrenia data, ADP Fast Track), but near-term risk is heavy: a 13.2M-share resale registration just went effective, the stock trades below its placement price, float is thin at ~18.8%, and beta is 2.57. Verdict: speculative and elevated-risk — a watchlist profile rather than a fundamentals-driven buy.
Sentiment
weakSentiment is negatively impacted by a recent resale registration and index deletion, with no bullish catalysts.
MPLT's 14-day media sentiment is determinate but weak: the delta improved from a bearish −0.30 baseline to −0.075 in the scoring window yet stayed slightly negative, and the actionable catalyst map is all-bearish — S&P Biotechnology Select Industry Index deletion (announced, 2026-09-21) plus the 2026-09-23 resale-registration supply overhang (regulator_confirmed) — with no rewarded bullish catalyst and indeterminate retail. Moderate red-flag cap applied (growth-context dilutive financing / resale supply overhang); no severe flags, regulator-confirmed investigations at zero.
Technical
weakThe stock is in a strong downtrend, trading below all key moving averages with no bullish setup.
Score 2: weak bearish / bounce-only. Oversold momentum (RSI14 29.3, Williams %R -91.9, positive MACD histogram +0.07) hints at a possible reflex bounce, but price 10.46 sits below every key average (SMA20 12.30, SMA50 15.17, SMA200 21.76, EMA9 11.17, EMA21 12.14), the MACD line remains negative (-1.26), and ADX14 34.2 read with the trend position confirms a strong DOWN trend. Independently of the chart, the fundamentalScore (2) and qualitativeScore (2) override gates are hard blocks.
You’re looking at 2026-09-25 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

